Issue 1: July 2014 MD Anderson Represented at The 4th International IBC Conference; Dr. Bedrich Eckhardt Recognized for Best Poster The 4th International Inflammatory Breast Cancer (IBC) Conference (http://www.ibcc.be/) was held in Antwerp, Belgium in early May. It was a great pleasure to meet with our colleagues who are equally committed to IBC research and patient care and to learn of exciting advances in the field. This conference, held every two years, provides an opportunity to establish and enhance collaborations and to share our knowledge and experience in IBC. Thirteen faculty and staff from the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic were in attendance; we had twelve oral presentations. Overall, we were proud to show our commitment to the IBC community by sending a large delegation. More importantly, we were able to demonstrate our contributions to major progress in IBC research. Among the selected presentations, Dr. Bedrich Eckhardt’s was chosen as the best poster presentation. He presented his project, “The bone morphogenetic protein signaling pathway is therapeutically exploitable in metastatic inflammatory breast cancer,” which investigated a gene that we have discovered to control metastatic potential in breast cancer. This gene, bone morphogenic protein-4 (BMP4), is a cytokine that is involved in the maintenance of tissue polarity and bone development. In the normal breast epithelium, BMP4 is highly expressed; however, we found that its expression is lost in invasive breast cancer. IBC is a clinic pathological subtype of invasive breast cancer and in our studies we found BMP4 expression to be lower than stage-matched locally advanced breast cancer. Moreover, low BMP4 expression correlated with poor prognosis for relapse-free survival in patients. In preclinical models, we demonstrated that restored BMP4 expression can block metastatic progression. Multiple lines of evidence suggested that BMP4 inhibited metastasis by stimulating quiescent canonical BMP signaling pathways, which led to a ‘stop metastasis’ gene signature being activated within the cancer cell. Collectively, Dr. Eckhardt’s data demonstrates the clinical potential of a new therapeutic target for aggressive and metastatic breast cancer. We extend a heartfelt congratulations to Dr. Bedrich Eckhardt for this accomplishment and well-deserved recognition. Issue 1: July 2014 Oral Presentations at 4th International IBC Conference Breast Imaging in IBC Wei Yang MD, Department of Radiology Invited Oral Presentation: Long-term outcome in patients with HER2-negative inflammatory breast cancer (IBC) treated with primary systemic chemotherapy Jie Willey MSN, Department of Breast Medical Oncology Future of targeted therapies in IBC Naoto Ueno MD, PhD, Department of Breast Medical Oncology Invited Oral Presentation: Role of HER2/CEP17 FISH ratios in predicting pathological complete response to neoadjuvant systemic chemotherapy with trastuzumab Takahiro Kogawa MD, PhD, Department of Breast Medical Oncology Radiotherapy Wendy Woodward MD, PhD, Department of Radiation Oncology Invited Oral Presentation: Src pathway mediates cancer stem cells through Notch signaling in inflammatory breast cancer Xiaoping Wang PhD, Department of Breast Medical Oncology Host factors involved in the establishment of the IBC phenotype Wendy Woodward MD, PhD, Department of Radiation Oncology Nursing Program: Prognosis – Follow-Up Pamela McCarthy OncNP, DNP, RN, AOCN, CBCN, Department of Breast Medical Oncology Invited Oral Presentation: The bone morphogenetic protein signaling pathway is therapeutically exploitable in metastatic inflammatory breast cancer Bedrich Eckhardt PhD, Department of Breast Medical Oncology Nursing Program: Metastatic disease: diagnosis and general management of survivorship Pamela McCarthy OncNP, DNP, RN, AOCN, CBCN, Department of Breast Medical Oncology Invited Oral Presentation: Epidemiologic factors associated with inflammatory breast cancer – An analysis of the inflammatory breast cancer registry at the University of Texas MD Anderson Cancer Center Tamer Fouad MD, PhD, Department of Breast Medical Oncology Nursing Program: Nursing research on inflammatory breast cancer Pamela McCarthy OncNP, DNP, RN, AOCN, CBCN, Department of Breast Medical Oncology Current Clinical Trials 2008-0372 Phase II Panitumumab, Nab-paclitaxel, and carboplatin HER2- IBC 2010-0296 TKI258 (Dovitinib Lactate) as Salvage Therapy HER2- MIBC 2010-0842 A phase I Entinostat and Lapatinib + Herceptin HER2+ MBC failed Herceptin 2006-1072 IBC Registry NSABPFB-7 (Neratinib) Neoadju Wkly Paclitaxel/Neratinib/ Trastuzumab F/AC with Postop Trastuzumab HER2 + IBC Current Lab Studies PA12-0453 EpCAM-CTC-EMT PA12-0728 TIL for TNBC and IBC PA12-0860 Assessing feasibility of sentinel lymph node increase dissection in IBC PA12-0097 Prognostic Utility of CTCs Assessed by Adnagen Technology and Clinical Outcome of Patients with Stage III Breast Cancer PA13-0799 Development of EMT-CTC chip
© Copyright 2024 ExpyDoc
